Concepedia

Publication | Closed Access

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.

24

Citations

0

References

2015

Year

Lore Decoster, Isabelle Vande Broek, Bart Neyns, F. Majois, Jean François Baurain, Sylvie Rottey, Andrée Rorive, Ellen Anckaert, Johan De Mey, Sylvia De Brakeleer,
PubMed

Abstract

Sunitinib demonstrates limited activity in unselected patients with refractory advanced melanoma, but a minority of patients experienced long-term disease control. Identification of these patients remains a challenge.